Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cyberonics (cybx) epilepsy therapy recommonded -- Ignore unavailable to you. Want to Upgrade?

To: Dennis who wrote (285)	4/25/1998 4:28:00 PM
From: fred woodall	Read Replies (1) \| Respond to of 471

Good news: CYBX has been upgraded from ''hold'' to ''buy'' by JB Oxford & Company. The company is maintaining its earnings estimates and its 12-18 month price target of $38.00 per share. Cyberonics markets an innovative treatment for epilepsy patients that incorporates its proprietary Vagus Nerve Stimulation (VNS) technology. The company's lead product, the NeuroCybernetic Prosthesis (NCP), is an implantable medical device similar to a pacemaker that delivers an electrical signal to the vagus nerve in the neck. The NCP systems is the only FDA-approved medical device for the treatment of epilepsy. Cyberonics received FDA approval for the NCP system in July of 1997 as a therapy for reducing the frequency of seizures in patients over twelve years of age with partial onset seizures that are refractory (resistant) to antiepileptic drugs. The company is currently seeking to broaden this initial indication to include expanded treatment of epilepsy and other neurological disorders.